Spark Therapeutics announced the price tag for its first-of-its-kind gene therapy for eye disease — $850,000 for both eyes.

The FDA approved Spark Therapeutics’ treatment for a rare form of blindness, marking the first time the U.S. regulatory agency approved a gene therapy for an inherited disease.